ClinicalTrials.gg
Not yet recruitingNCT07916974Updated Nov 4, 2026

Parent-Based Intervention for Childhood Avoidant/Restrictive Food Intake Disorder (ARFID)

An interventional study of Supportive Parenting for Anxious Childhood Emotions (SPACE) and Nutritional Support (NS) in Anxiety Disorder of Adolescence and Avoidant / Restrictive Food Intake Disorder, sponsored by Yale University. Not yet recruiting at 1 site in United States. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Yale University · Not applicable, Interventional, and Treatment

Updated Nov 4, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Study summary

This study aims to test the efficacy of a parent-based approach to treating Avoidant/Restrictive Food Intake Disorder (ARFID) in children, SPACE-ARFID (Supportive Parenting for Anxious Childhood Emotions, adapted for ARFID), by comparing it to Nutritional Support (NS). The study design is a randomized controlled trial with 2 treatment arms and 3 assessment points (pre, post, and follow-up) using questionnaire data and clinical interviews.

Read the detailed description

The primary objective is to examine if SPACE-ARFID is more efficacious than NS in reducing adolescent ARFID symptoms. The secondary objective is to examine if SPACE-ARFID produces greater change than NS in improving family accommodation and family functioning. SPACE and NS will be delivered over 16-20 weekly sessions, pre-assessment will take place before sessions begin and post-assessment will take place once sessions end, there will also be a midpoint assessment halfway through treatment (sessions 8-10) and one more follow-up assessment 6 months later.

02

Conditions studied

  • Anxiety Disorder of Adolescence
  • Avoidant / Restrictive Food Intake Disorder
03

In context

Avoidant Restrictive Food Intake Disorder

40 studies on the registry are indexed under Avoidant Restrictive Food Intake Disorder; 12 are open to participants now.

This study's planned enrollment of 110 is above the median of 38 across 28 interventional studies indexed under Avoidant Restrictive Food Intake Disorder.

Browse Avoidant Restrictive Food Intake Disorder studies →

Lead sponsor

Yale University is the lead sponsor of 1,770 studies on the registry; 294 are open to participants now.

Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be between 6 and 12 years old.
  • Meet diagnostic criteria for ARFID, as determined by the PARDI diagnostic interview.
  • Cease all other psychotherapeutic treatment targeting eating or feeding behaviors, upon consultation with project staff and the current service provider.
  • Not currently use any psychotropic medication, unless on a stable dose for a minimum of 4 weeks prior to enrollment; no changes anticipated during the course of the study.
  • at or above the 5th percentile for age and sex.
  • Have an eligible and willing participating parent (see parent exclusions below).

Exclusion criteria

Exclusion Criteria:

Adolescents:

  • Meet criteria for any other disorder as determined by the ADIS diagnostic interview and health history form, that is sufficiently impairing or disruptive so as to make treatment focused on ARFID not feasible.
  • Have any of the following disorders: intellectual disability; bipolar disorder; schizophrenia and other psychotic disorders; and alcohol and substance use disorders, as determined by the health history form.
  • Report a suicide attempt in the last 3 months, or current suicide intent and/or plans.
  • Be a victim of past or present undisclosed abuse requiring investigation or ongoing supervision by the Department of Children and Families.
  • Not have sufficient proficiency in English to complete assessments.
  • Require a level of medical care for nutritional compromise that exceeds what can be safely provided in an outpatient setting.

Parents:

  • Have any of the following: intellectual disability; untreated bipolar disorder; untreated schizophrenia and other psychotic disorders; and untreated alcohol and substance use disorders, report a suicide attempt in the last 3 months, or current suicide intent and/or plans.
  • Not be living with the child at least 50% of the time.
  • Not have sufficient proficiency in English to complete assessments and participate in treatment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Supportive Parenting for Anxious Childhood Emotions (SPACE)

    Parent-only approach to treating anxiety disorders in adolescents delivered over 16-20 sessions.

    Behavioral: Supportive Parenting for Anxious Childhood Emotions (SPACE)

  • Active comparator
    Nutritional Support (NS)

    Parent-only approach comparator arm delivered over 16-20 sessions.

    Behavioral: Nutritional Support (NS)

Interventions

  • BehavioralSupportive Parenting for Anxious Childhood Emotions (SPACE)

    Parent-based treatment delivered by therapist for 16-20 weekly sessions.

  • BehavioralNutritional Support (NS)

    Nutritional Support from Registered Dietician for 16-20 weekly sessions with parents.

06

What researchers measure

Primary outcomes

  1. Pica, ARFID, and Rumination Disorder Interview (PARDI-C/P)

    This semi-structured clinical interview will assess ARFID presence and severity. Symptoms are rated on a 0 (no symptoms) to 6 (severe symptoms) scale. It yields an overall severity score and three profile scores (sensory sensitivity, lack of interest in eating or food, fear of aversive consequences). Score range = 0 to 6 with higher scores indicating greater severity.

    Time frame: Weeks 1 and 16-20

  2. Nine-Item Avoidant/Restrictive Food Intake Disorder Screen - Parent and Child Report (NIAS-C/P)

    This measure is a screener of ARFID severity. It contains 9 items, each rated on a 6-point scale from 0 ("strongly disagree") to 5 ("strongly agree"). It yields a total score and three subscale scores (picky/selective eating, poor appetite/limited interest, fear of negative consequences). Total score range = 0 to 45, with higher scores indicating greater severity.

    Time frame: Weeks 1, 8-10, 16-20 and 6 months later

  3. Clinical Global Impression Scale - Severity (CGI-S) and Improvement (CGI-I)

    This measure will be used to assess overall severity (CGI-S) and improvement (CGI-I) in adolescent ARFID. Total score range for each is 1-7. (Scores of 1 ("very much improved/normal") or 2 ("much improved/borderline ill") indicate a positive treatment response; all other responses are considered negative responses. Higher scores indicate worse outcome.

    Time frame: Weeks 1 and 16-20

Secondary outcomes

  1. Children's Food Neophobia Scale - six item version (CFNS-6)

    This measure of children's reluctance to try new or unfamiliar foods contains 6 items rated on a 4-point scale from 1 ("strongly disagree") to 4 ("strongly agree"), with 2 items reverse-scored. Total score range = 1 to 24, with higher scores indicating greater food neophobia.

    Time frame: Weeks 1, 8-10, 16-20 and 6 months later

  2. Caregiver Strain Questionnaire (CGSQ)

    This scale will measure the strain caregivers experience as a result of their child's emotional and behavioral problems. It contains 21 items, each rated on a 5-point scale from 1 ("not at all a problem") to 5 ("very much a problem") for how much each occurrence or feeling was a problem in the past 6 months. The items form three subscales: objective strain (11 items), subjective internalized strain (6 items), and subjective externalized strain (4 items). Subscale and global scores are item means, 1 item ("relating well to child") is reverse scored. Scores range = 1 to 5, with higher scores indicating greater strain.

    Time frame: Weeks 1, 8-10, 16-20 and 6 months later

  3. Parent-Rated Food Flexibility Scale (FFS)

    This scale is a 10-item parent-report measure of the child's tolerance of variability across food-related domains. Parents rate each domain on a 5-point scale from 0 ("very inflexible") to 4 ("very flexible"), with "mostly inflexible" (1), "some flexibility" (2), and "mostly flexible" (3) in between. Ratings are summed to a total score (range = 0 to 40), with higher scores indicating greater flexibility.

    Time frame: Weeks 1, 8-10, 16-20 and 6 months later

  4. Acceptance and Confidence Scale - Anxiety

    This scale is a measure of the extent to which parents express acceptance of and confidence in the face of their child's anxiety, a key clinical target of SPACE. It contains 8 items, each rated on a 6-point scale from 1 ("strongly disagree") to 6 ("strongly agree"). Total score range = 8 to 48, with higher scores indicating greater acceptance and confidence.

    Time frame: Weeks 1, 8-10, 16-20 and 6 months later

  5. Weekly Food Update

    This brief questionnaire tracks changes in the child's eating over the course of treatment. Parents complete it before each weekly session, thinking back over the past week. The form has two parts. In the first, parents indicate whether their child ate each food already being tracked, and if so, how much (a taste, some, or a full portion), and whether the child now eats it regularly. In the second, parents record foods that are new that week: foods the child has never eaten before, foods the child is eating again after a long period of avoidance, and familiar foods eaten in a new way (for example, a different brand, preparation, or setting).

    Time frame: Weeks 1-20

  6. Parent-completed Glasgow Sensory Questionnaire, short form (rGSQ-P)

    This scale has 24 items and measures children's sensory hyper- and hypo-sensitivity across six sense domains (visual, auditory, gustatory, olfactory, tactile, vestibular). Parents rate items on a 5-point scale from 0 ("never") to 4 ("always"), yielding total (0-96), hyper-sensitivity (0-48), and hypo-sensitivity (0-48) scores, with higher scores indicating greater sensory sensitivity.

    Time frame: Weeks 1, 8-10, 16-20 and 6 months later

  7. Client Satisfaction Questionnaire (CSQ-8)

    This 8-item measure assesses client satisfaction. Parents and adolescents rate items on a 0-4 scale, with higher summed scores indicating greater satisfaction with services (range = 0 to 32).

    Time frame: Week 16-20

Other outcomes

  1. Family Accommodation Scale - Anxiety (FASA-C/P)

    This scale is a widely used measure of family accommodation. Adolescents and parents rate 9 items on a 5-point scale from 0 ("never") to 4 ("daily"). Total score range = 0 to 36.

    Time frame: Weeks 1 and 16-20

  2. Family Assessment Device - General Functioning Scale (FAD-GF)

    This scale measures overall family functioning. Adolescents and parents rate 12-items on a 4-point scale from 0 ("strongly disagree") to 3 ("strongly agree"). Total score range = 0 to 36.

    Time frame: Weeks 1 and 16-20

07

Study locations

1 site
  • Yale Child Study Center
    New Haven, Connecticut 06519, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07916974
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Nov 4, 2026
Start date
Dec 2026 (estimated)
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 4, 2026

Study contacts

Eli Lebowitz, PhD
Contact
eli.lebowitz@yale.edu
203-737-4644
Alison Magnotti, MA
Contact
alison.magnotti@yale.edu
203-737-4644
Eli Lebowitz
principal investigator · Yale University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion